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ABBREVIATIONS
BPSU British Paediatric Surveillance
Unit
NCJDRSU National Creutzfeldt-Jakob
disease Research and
Surveillance Unit
PIND Progressive intellectual and
neurological deterioration
vCJD Variant Creutzfeldt-Jakob
disease
AIM To report the differential diagnosis in children with progressive intellectual and
neurological deterioration (PIND) in the UK.
METHOD Since 1997 the PIND Study has searched for variant Creutzfeldt-Jakob disease
(vCJD) in children, using the British Paediatric Surveillance Unit to perform prospective
surveillance of those younger than 16 years with PIND.
RESULTS From May 1997 to October 2019, 2255 children meeting PIND criteria had been
notified, of whom 2008 (1085 males, 923 females) had underlying diagnoses. There were over
220 different diseases, including six cases of vCJD. The numbers presenting in four age
groups were: <1 year, 805 (40%); 1 to 4 years inclusive, 825 (41%); 5 to 9 years inclusive, 264
(13%); and 10 to 15 years inclusive, 114 (6%). The two largest ethnic groups were White and
Pakistani (58.2% and 17% of diagnosed cases). The most common diseases in these two
ethnic groups are shown for the four age groups. The distribution of diseases varied with
age but was quite similar in White and Pakistani children.
INTERPRETATION This paper provides a unique guide to the complex differential diagnosis of
childhood PIND, showing considerable differences between four age groups, but similarities
between ethnic groups. The PIND Study still provides the only systematic surveillance for
vCJD in children in the UK.
The first cases of variant Creutzfeldt-Jakob disease (vCJD)
in young adults were reported by the National Creutz-
feldt-Jakob Disease Research and Surveillance Unit
(NCJDRSU) in 1996.1 This raised the possibility that
vCJD might occur in children. As there is no validated
screening test for vCJD it is necessary to search systemati-
cally for cases of vCJD among the many neurodegenerative
disorders of childhood. That is why the study of progres-
sive intellectual and neurological deterioration (PIND) was
set up in 1997, using the well-established system pioneered
by the British Paediatric Surveillance Unit (BPSU).2,3 Pae-
diatricians in the UK are asked to notify all patients aged
younger than 16 years with PIND because this group of
children is likely to include any cases of vCJD. There is
still a risk that children could develop vCJD, so PIND
surveillance continues.4
Most of the notified children who meet the study criteria
for PIND have an underlying diagnosis other than vCJD
to explain their deterioration, and an independent PIND
Study Expert Group validates those diagnoses. Since 1997,
the PIND Study has provided a unique, on-going review
of the distribution of rare neurodegenerative diseases in
children in the UK. The study has previously reported that
some UK paediatric centres notify relatively large numbers
of cases with a high proportion of children of Pakistani
origin.4,5 This paper provides clinicians with an age-related
differential diagnosis in children with PIND, concentrating
on the two largest ethnic groups in the PIND Study
(White and Pakistani).
METHOD
Since 1986, the BPSU has studied many rare childhood
disorders. All UK consultant paediatricians are requested
to notify children with one of the conditions under surveil-
lance using a monthly online system asking for notifica-
tions of all children seen in that month who meet the case
definition for PIND (Table 1), even if a diagnosis has
already been made (see the BPSU section of the Royal
College of Paediatrics and Child Health website).6
Clinical information is obtained via a questionnaire com-
pleted by the notifying paediatrician, via telephone inter-
view or by site visit; there is no contact with patients or
families. The questionnaire records information about pre-
senting symptoms and signs and follows progress after pre-
sentation. It also enquires about the child’s ethnic origin,
using the classification that was used by the Public Health
Laboratory Service in 1997: White, Black Caribbean, Black
African, Black other, Indian, Pakistani, Bangladeshi,
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Chinese, Other. The clinical data are anonymized and then
reviewed by an independent PIND Expert Group to con-
firm and classify diagnoses. The Group consists of paedi-
atric neurologists, specialists in genetics and paediatric
metabolic disease, together with representatives from the
NCJDRSU. If vCJD is suspected it is suggested that the
local paediatrician obtains consent to refer the child to the
NCJDRSU in Edinburgh. Otherwise, the notified children
are followed up by the PIND team via the local clinician
until: (1) a definite diagnosis is made, (2) no further inves-
tigations are planned, or (3) the child dies.
As recommended by Foss et al.,7 the lifetime risk at
birth was calculated for the cases of confirmed PIND by
dividing the number of diagnosed cases by the number of
total births during the relevant diagnosis period.
The PIND Study was approved by the National
Research Ethics Committee East of England Cambridge
Central (ref 97/010). The Public Health England Caldicott
Advisory Panel has agreed that patient identifiable informa-
tion can be processed without consent under Regulation 3
of the Health Service (Control of Patient Information)
Regulations 2002. The Public Benefit and Privacy
Panel for Health and Social Care (Scotland) has similarly
approved the PIND Study.
RESULTS
Between May 1997 and October 2019, 4612 children had
been notified to the PIND Study. After an initially large
number of notifications of prevalent cases in the first 20
months of the study, the number of notified cases of sus-
pected PIND settled over the period 1999 to 2018 inclu-
sive to between 146 and 230 per year (median 188.5/year);
this notification rate has continued to be relatively con-
stant. The number of confirmed cases of PIND that had
been fully investigated was 2255; 2073 cases were not
included (1023 cases did not meet the PIND criteria, there
were reporting errors/duplicate notifications in 786, and
clinical details were not forthcoming in 264 cases). A fur-
ther 284 were either still under investigation or clinical
details were pending. The lifetime risk at birth of having a
disease causing PIND was calculated using the 1703 diag-
nosed cases meeting the PIND criteria who were notified
between the beginning of 1999 and the end of 2018, when
numbers had settled to a relatively steady level of incident
cases. During that period there were 14 935 076 live births
in the UK,8 so the lifetime risk of having a disease causing
PIND was 0.1 per 1000 live births.
Of the 2255 children notified between 1997 and 2019
who met PIND criteria and had been investigated, 247 did
not have an underlying diagnosis to explain their deteriora-
tion: all investigations had been negative, or they had died
undiagnosed. That left 2008 (1085 males, 923 females)
with a known underlying diagnosis, with over 220 different
disorders including six cases of vCJD. In these 2008 cases
the age at presentation (defined as the age at which the
child first developed symptoms or clinical signs) was deter-
mined from the clinical records. On this basis the cases
were allocated to four different age groups: <1 year: 805
(40%); 1 to 4 years inclusive: 825 (41%); 5 to 9 years
inclusive: 264 (13%); 10 to 15 years inclusive: 114 (6%);
thus 81% presented before 5 years of age. The distribution
by ethnic origin was: White 58.2%, Black 1.9%, Indian
1.3%, Pakistani 17%, Bangladeshi 2.2%, Chinese 0.25%,
Other (other ethnic groups, mixed race, unknown, etc.)
19%. Of the 340 children in the Pakistani group, 294
(86%) had consanguineous parents and 17 (5%) did not; in
29 (9%) that information was not available. In contrast,
only 3% of the 1169 White children had consanguineous
parents, although information about consanguinity was not
available for 21% of the White children.
The most common of these rare disorders in the two
largest ethnic groups (White and Pakistani) in the four age
groups given above are shown in Figures 1 to 4 and the
‘others’ (those White and Pakistani children who are not
shown in the figures) are listed in Tables S1 to S4 (online
supporting information). For example, in the <1 year age
group there were 452 White children: 302 of these are
included in the 11 most common diagnoses shown in
Figure 1a and 150 ‘others’ are listed in Table S1. Also in
the <1 year group were 169 Pakistani children: 107 of
these are included in the 11 most common diagnoses
shown in Figure 1b and 62 ‘others’ are listed in Table S1.
Similar details about the composition of the other age
groups are shown in the legends for Figures 1 to 4. The
Table 1: Case definition – progressive intellectual and neurological
deterioration
Any child (under 16y of age at onset of symptoms) who fulfils all
of the following three criteria:
Progressive deterioration for more than 3mo;
Loss of already attained intellectual or developmental abilities;
and
Development of abnormal neurological signs
Excluding
Static intellectual loss (e.g. after encephalitis, head injury, or
near drowning)
Including
Children who meet the case definition, even if specific
neurological diagnoses have been made
Metabolic disorders leading to neurological deterioration
Seizure disorders if associated with progressive deterioration
Children who have been diagnosed as having
neurodegenerative disorders who have not yet developed
symptoms
Reporting restricted to cases seen in the last month but
including those whose condition began earlier (i.e. including
‘old cases’ of children in follow-up if seen in that month)
What this paper adds
• The prevalence of diseases causing childhood progressive intellectual and
neurological deterioration in the UK is low (approximately 0.1/1000 live
births).
• There were more than 220 different disorders, mainly genetically deter-
mined.
• The majority of disorders presented early in childhood: 81% before the age
of 5 years.
• There were similarities in the disease spectrum in White and Pakistani chil-
dren.
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White and Pakistani cases that are not shown in the figures
(see also Tables S1–S4) had a heterogeneous mixture of
diseases. For instance, in the <1 year age group, the White
‘others’ group included 59 diseases and the Pakistani
‘others’ group included 36 diseases. There were 1169
White and 340 Pakistani children, leaving 499 children for
whom details about the diagnoses are not included in this
paper because (1) the other ethnic groups were so small
and (2) the ethnicity of the remainder was not known.
It can be seen in Figures 1 to 4 that there are differences
in the distribution of diseases according to age. In contrast,
there was considerable overlap in the distribution of disease
found in White and Pakistani children of a given age. For
example, Figure 1a shows the 11 most common diseases in
the White children aged <1 year; six of these diseases were
also found among the 11 most common diseases in the Pak-
istani children in the same age group, as shown in Figure 1b.
If the diseases that were less common in that Pakistani age
group are also considered (see Table S2), then nine of the
11 most common diseases found in the White children were
found in Pakistani children of the same age. There were
similar findings in other age groups.
For simplicity, some disorders have been grouped. For
instance, among White children in the first year of life
Alexander, 10(a)
(b)
AGS, 11
GM1, 13
Sandhoff, 15
Rett, 23
Menkes, 23
Tay-Sachs, 37
Krabbe, 42
Mito, 98
Mito, 37
AGS, 15
Krabbe, 5
I-Cell dis, 5
Zellweger, 6
Leuk, 6
Tay-Sachs, 6
Cockayne, 6
Canavan, 7
GM1, 8
Mo co-fact def,
6
MPS I, 10
Zellweger
spectrum, 20
Figure 1: rogressive intellectual and neurological deterioration diagnoses in (a) White and (b) Pakistani children <1y. Eleven most common diagnoses
in White (n=302) and Pakistani (n=107) children age <1y. The White (n=150) and Pakistani (n=62) children with ‘other’ diagnoses are shown in Table S1.
AGS, Aicardi-Goutieres syndrome; GM1, GM1 gangliosidosis; Leuk, unclassified leukoencephalopathies; Mito, mitochondrial disorders; Mo co-fact def,
molybdenum co-factor deficiency; MPS I, mucopolysaccharidosis type I; Zellweger spectrum, Zellweger spectrum disorder (includes Zellweger syn-
drome, neonatal adrenoleukodystrophy, and infantile Refsum disease).
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there were 98 cases with mitochondrial diseases, made up
of 21 different mitochondrial diagnoses, also the diseases
included in the Zellweger spectrum disorder were grouped
together (see Fig. 1a). In White children aged 1 to 4 years
there were 109 cases of neuronal ceroid lipofuscinosis,
made up of eight different neuronal ceroid lipofuscinosis
diagnoses (see Fig. 2a).
White children with mucopolysaccharidosis type III
were most likely to present at age 1 to 4 years. A large
proportion of children with neurodegeneration with brain
iron accumulation were in this age group. There were
three different neurodegeneration with brain iron accumu-
lation diagnoses (shown in Fig. 2a,b, and Table S2): pan-
tothenate kinase-associated neurodegeneration, PLA2G6-
associated neurodegeneration, and beta-propeller protein-
associated neurodegeneration. Children with Rett syn-
drome lose skills towards the end of the first year of life
and are among the most common PIND cases of White
children in the <1 year and the 1 to 4 year age groups.
However, older children with Rett syndrome are more
VWMD, 12
(a)
(b)
PLAN, 12
NP-C, 15
ALD, 24
Rett, 42
Mito, 44 MLD, 47
Mito, 16
NCL, 15
PLAN, 15
Sandhoff, 14
Leuk, 4
NP-C, 4
A-T, 4
MPS III, 9
MLD, 10
PKAN, 6
NCL, 109
MPS III, 65
Tay-Sachs
11
Figure 2: Progressive intellectual and neurological deterioration diagnoses in (a) White and (b) Pakistani children 1–4y. Ten most common diagnoses in
White (n=381) and Pakistani (n=97) children age 1–4y. The White (n=96) and Pakistani (n=37) children with ‘other’ diagnoses are shown in Table S2.
ALD, adrenoleukodystrophy; A-T, ataxia-telangiectasia; Leuk, unclassified leukoencephalopathies; Mito, mitochondrial disorders; MLD, metachromatic
leukodystrophy; MPS III, mucopolysaccharidosis type III; NCL, neuronal ceroid lipofuscinoses; NP-C, Niemann-Pick type C; PKAN, pantothenate kinase-
associated neurodegeneration; PLAN, PLA2G6-associated neurodegeneration; VWMD, vanishing white matter disease.
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stable neurologically and do not meet the study criteria,
leading to under-ascertainment of Rett syndrome cases.
In the 5 to 9 year and 10 to 15 year groups, Rasmussen
syndrome and Huntington disease appear in White chil-
dren (there was no case of Huntington disease in the
Pakistani group).
The differential diagnosis in the White children in the
10 to 15 year age group includes all six children with
vCJD notified to the PIND Study between 1998 and 2001.
The youngest was a female who developed symptoms at
age 12 years. The clinical features in these children were
similar to those in adults with vCJD (neuropsychiatric fea-
tures, new ataxia, cognitive decline). The investigations
that were used to confirm the diagnosis in children were
the same as those used in adults (e.g. the pulvinar sign on
brain magnetic resonance imaging and post-mortem neu-
ropathological findings).3
It is notable that new cases of subacute sclerosing panen-
cephalitis disappeared for a time. By October 2019, 13
cases of subacute sclerosing panencephalitis had been noti-
fied and confirmed. Of these, eight were White children:
one in the 1 to 4 year group (Table S2), three in the 5 to
9 year group (Fig. 3a), and four in the 10 to 15 year group
(Fig. 4a). One was a Pakistani child in the 5 to 9 year
group (Table S3); three were in other ethnic groups, and
in one ethnicity was unknown. Of the 13 subacute scleros-
ing panencephalitis cases, nine had developed symptoms in
or before 2002. There was then a gap of 14 years until a
child was reported who had developed symptoms in 2017,
and three more followed. Subacute sclerosing panencephalitis
PKAN, 3
MLD, 4
NCL, 5
Juv
Sandhoff, 5
ALD, 29
NCL, 45
SSPE, 3
Mito, 15
Hypomyelin, 3(a)
(b)
NP-C, 12
MLD, 11
Huntington,
11
Rasmussen, 5
Juv
Alexander, 4
PKAN, 4
Juv
Sandhoff, 3
Figure 3: Progressive intellectual and neurological deterioration diagnoses in (a) White and (b) Pakistani children 5–9y. Twelve most common diagnoses
in White (n=145) children age 5–9y and four most common diagnoses in Pakistani (n=17) children age 5–9y. The White (n=18) and Pakistani (n=10) chil-
dren with ‘other’ diagnoses are shown in Table S3. ALD, adrenoleukodystrophy; Hypomyelin, hypomyelination; Juv, juvenile; Mito, mitochondrial disor-
ders; MLD, metachromatic leukodystrophy; NCL, neuronal ceroid lipofuscinoses; NP-C, Niemann-Pick type C; PKAN, pantothenate kinase-associated
neurodegeneration; SSPE, subacute sclerosing panencephalitis.
Differential Diagnosis of PIND Christopher Verity et al. 5
is a late complication of measles infection, so it seems likely
that the recurrence of cases results from falling measles vacci-
nation uptake. The number of confirmed cases of measles (in
adults and children) in England and Wales increased from 56
in 1998 to a peak of 2032 in 2012; in 2018 it was 989.9
DISCUSSION
Background
Until 2016, all the 177 deaths from definite and probable
cases of vCJD10 had occurred in patients who were
methionine homozygous at codon 129 of the PRNP
gene. However, in January 2017 it was reported that
vCJD had been confirmed in a UK male who was
methionine/valine heterozygous at PRNP codon 129.11
In the general UK population, about 44% have the
methionine homozygous genotype and 45% are
methionine/valine,12 raising the possibility of a second
wave of vCJD cases in those with the methionine/valine
genotype. Also, there are concerns about surgical13 and
blood-borne transmission,14 so there is a need for con-
tinuing national surveillance for vCJD. UK surveillance
for prion diseases is carried out by the NCJDRSU, the
team that first identified vCJD,1 relying on neurologists,
psychiatrists, neuropathologists, and other clinical spe-
cialists to report adults with suspected vCJD. When
planning surveillance in children it was clear that vCJD
cases could be hidden among the multitude of rare neu-
rodegenerative diseases of childhood, so a system of
direct referral of suspected vCJD cases would not be
reliable. Therefore, since 1997 the PIND Study has
MLD, 2 PKAN, 2 Leuk, 2
Mito, 12
ALD, 8
NP-C, 6
vCJD, 6
Cobal def, 3
Juv
Sandhoff, 1
PKAN, 1
Astro, 1
Juv Tay-
Sachs, 1
Lafora, 3
Juv
Alexander, 2
(a)
(b)
Rasmussen, 3
Wilson, 4
SSPE, 4
NCL, 4
Lafora, 5
Huntington, 5
Figure 4: Progressive intellectual and neurological deterioration diagnoses in (a) White and (b) Pakistani children 10–15y. Fourteen most common diag-
noses in White (n=65) children age 10–15y and six most common diagnoses in Pakistani (n=10) children age 10–15y. The White (n=12) children with
‘other’ diagnoses are shown in Table S4. ALD, adrenoleukodystrophy; Astro, astrocytoma; Cobal, cobalamin deficiency; Juv, juvenile; Leuk, unclassified
leukoencephalopathies; Mito, mitochondrial disorders; MLD, metachromatic leukodystrophy; NCL, neuronal ceroid lipofuscinoses; NP-C, Niemann-Pick
type C; PKAN, pantothenate kinase-associated neurodegeneration; SSPE, subacute sclerosing panencephalitis; vCJD, variant Creutzfeldt-Jakob disease.
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asked paediatricians to notify all the children in the UK
with PIND, looking for vCJD cases among them.
Strengths of the study
The PIND Study uses the health surveillance mechanism
of the BPSU.2 There is multisource ascertainment and the
reporting is not restricted to cases admitted to hospital. All
the cases reported are investigated according to normal
practice via the usual networks established by community
paediatricians, general paediatricians, and other specialists
(e.g. geneticists, paediatric neurologists, metabolic special-
ists, neuropathologists, and others), so information about
cases is available from general paediatrics and sub-special-
ists. The PIND Study team makes no contact with the
patient or the family and does not become involved in the
management of cases.
Notified children are followed via the notifying paedia-
trician until they are diagnosed, until no further investiga-
tions are planned, or until the child dies. It is a strength of
the study that all suspected PIND cases are reported, even
if many are later excluded because their clinical course
does not fit the study criteria. By October 2019, the PIND
Study Expert Group had agreed a diagnosis in 2008 con-
firmed cases of PIND, thus providing an independent vali-
dation of more than 220 known neurological disorders.
The PIND Study has published case series of some of the
diagnosed groups.15–18
The PIND Study protocol stipulates that paediatricians
who report children with suspected vCJD are advised to
refer those children to the NCJDRSU. All six children in
the UK with vCJD were notified to the PIND Study and
were also investigated by the NCJDRSU. If the PIND
Study had not been in operation these children might not
have been ascertained by the NCJDRSU surveillance pro-
gramme, because it focusses on adults. No new childhood
vCJD cases have been identified in the UK since 2001.
The last adult vCJD case in the UK was diagnosed in
2016.11 The hope is that no new cases of vCJD will occur,
but the risk remains.
Limitations of the study
The BPSU relies on the voluntary support of consultant
paediatricians: it does not provide complete ascertainment
of cases and it is not always possible to obtain all the rele-
vant data about individual cases. After PIND cases have
been diagnosed they are not systematically followed up by
the PIND Study and follow-up has to be discontinued,
eventually, in undiagnosed cases, including some cases who
are transferred to adult care. It should be born in mind
that this study does not provide a guide to all neurodegen-
erative diseases in children as many do not meet the case
definition for PIND.
Comparison with other studies
There is a very specific case definition for the PIND Study
(see Table 1) and it is difficult to find other prospective
epidemiological studies that can be used for comparison. A
study in Norway identified all children born in one city
(Oslo) who had a ‘progressive childhood encephalopathy’
and found that the overall cumulative incidence of progres-
sive childhood encephalopathy among 138 550 live births
was 0.6 per 1000.19 The PIND study found a lifetime risk
at birth of 0.1 per 1000 live births – a similar calculation
to that used for the Oslo study. The lower PIND Study
rate may be partly explained by the PIND case definition,
which would have excluded some cases included in the
Norwegian study. Also, 531 PIND Study cases were not
eligible for estimating lifetime risk because they were still
under investigation (n=284) or had been investigated with-
out a diagnosis being made (n=247).
Distribution of diseases by age and ethnicity
A previous paper generated by the PIND Study reported
on the distribution of diseases found in notified children;20
these cases were not divided according to age or ethnic
group. A separate paper reported that in some parts of the
UK there were relatively large numbers of PIND cases
compared with the wider UK population, with a high pro-
portion from consanguineous families of Pakistani origin.5
A more recent paper reported the relatively large numbers
of British Asian children in PIND Study cases who were
undiagnosed despite careful investigation; in 89% of the
undiagnosed Pakistani children the parents were consan-
guineous.4
Figures 1 to 4 show considerable differences in the dif-
ferential diagnosis of PIND according to age. Some disor-
ders have been grouped to simplify the picture. In the first
year of life, the mitochondrial disorders made up the lar-
gest group. Mitochondrial diseases often present with a
relatively non-specific picture,15 so it is important to con-
sider them in young infants with PIND. Children with
PIND mainly have genetically determined neurometabolic
or neurodegenerative diseases, which present early in life
(81% of the PIND cases developed symptoms or signs
before 5y of age). The Oslo study also found a strong
reduction in incidence rates with increasing age.19
This paper reports the differences in the distribution of
diseases in the two biggest ethnic groups – White and Pak-
istani (58.2% and 17% of the diagnosed cases respectively).
Of the 340 Pakistani children, 86% had consanguineous
parents. The Pakistani group included many different fami-
lies with a wide spectrum of disorders. There were some
differences between White and Pakistani children, for
instance, there was no case of Menkes disease in the Pak-
istani children. However, there was considerable similarity
in the patterns of disease found in these two groups of
children from very different ethnic backgrounds.
CONCLUSIONS
The diagnosis of vCJD can only be confirmed or excluded
with certainty by neuropathological study. If ante-mortem
brain biopsies or post-mortem studies of brain tissue were
always performed in children with undiagnosed neurode-
generative diseases, then vCJD would be detected and
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there would be no need for the PIND Study. However, we
have previously reported that the undiagnosed children in
the PIND Study rarely underwent ante- or post-mortem
pathological examination of brain tissue4 and this seems
unlikely to change. Therefore, in the absence of an alterna-
tive validated vCJD screening test, the PIND Study
remains the only practical means of performing systematic
surveillance for vCJD in children in the UK. The aim of
this paper is to help paediatricians by providing unique
data about the age-related differential diagnosis in children
presenting with PIND.
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